Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Optomed

1.51 EUR-1.05 %30.9, 17.29
5,663 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
-1.05 %
-11.18 %
-15.55 %
-35.74 %
-59.95 %
-59.08 %
-44.38 %
-86.46 %
-67.03 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
32.46M EUR
Turnover
31.41K EUR
P/E (adj.) (26e)
-11.93
EV/EBIT (adj.) (26e)
-8.44
P/B (26e)
1.52
EV/S (26e)
1.56
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.00 EUR
Updated
17.08.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 17.08.2026

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
I understand that patience is wearing very thin. I am also very disappointed in myself, because I thought this would be a much quicker case, despite having worked in the healthcare sector for quite a long time. I should have understood that the speed of implementing new things is...
yesterday
by Kulukurssi
18
same here, I’ll be watching this one, but in the future I won’t touch these small-time kiosks with a ten-foot pole anymore. Even the latest option update here was like pissing on the shareholders. We’ll look after our own interests and improve our positions if it breaks out. What...
yesterday
by Velkku
14
I remember hearing something like that in an interview as well. Unfortunately, my own belief in this story is starting to be put to the test, even though I have actively been digging / trying to dig into what is happening beneath the surface. This continuous, awkward radio silence...
yesterday
by Mr. Stock
9
Good day! Development just keeps on developing… Little by little, algorithms are evolving, and it is becoming possible to detect a wide range of diseases from fundus images. Now an algorithm has been developed that detects six different diseases. Copy of the article. “”“”“”“”“”" ...
11 hours ago
by j.sälli
8
So the question is right there… IF they are shipping 5/10 pcs a day. IF they had shipped, say, over a couple of years, even just 2/day, the RR revenue should look completely different. When you combine this with the fact that there is very little pictures/information about installations...
yesterday
by Mr. Stock
6
By the way, this is worth keeping in mind… now that AEYE is selling the lion’s share of the US AI Aurora business, indeed with Opto, revenue is growing slowly, but profitability is all the more impressive. Perhaps if Opto had a larger sales share and thus higher revenue while the...
yesterday
by Puutaheinää
5
A camera sold through a Capex deal can only be sold once. Maybe maintenance on top of that when the device falls off the table. After the sale, the camera can be used to take, say, 50 pictures a month, which are sent along with a request for interpretation to “reading centers” for...
yesterday
by Dr.Feelgood
5
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.11
2026

Interim report Q3'26

18.2
2027

Annual report '26

4.5
2027

Interim report Q1'27

Regulatory press release28.09.2026, 15.17

Optomed Oyj - Managers' Transactions - Piila

Optomed
Regulatory press release28.09.2026, 15.15

Optomed Oyj - Managers' Transactions - Piila

Optomed
Regulatory press release28.09.2026, 15.15

Optomed Oyj - Managers' Transactions - Piila

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release28.09.2026, 15.15

Optomed Oyj - Managers' Transactions - Piila

Optomed
Regulatory press release28.09.2026, 15.12

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release28.09.2026, 15.10

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release28.09.2026, 15.10

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release28.09.2026, 15.10

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release28.09.2026, 15.07

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release28.09.2026, 15.05

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release28.09.2026, 15.05

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release28.09.2026, 15.05

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release28.09.2026, 15.01

Optomed Oyj - Managers' Transactions - Himberg

Optomed
Regulatory press release28.09.2026, 15.00

Optomed Oyj - Managers' Transactions - Himberg

Optomed
Regulatory press release28.09.2026, 15.00

Optomed Oyj - Managers' Transactions - Himberg

Optomed
Regulatory press release28.09.2026, 15.00

Optomed Oyj - Managers' Transactions - Himberg

Optomed
Regulatory press release25.09.2026, 14.30

Optomed Oyj: Optomed's Board of Directors has resolved to establish a new stock option plan

Optomed
Optomeds dattercelskab Ubetec har vundet Veikkauses udbud
Analyst Comment07.09.2026, 06.55 by
Juha Kinnunen

Optomeds dattercelskab Ubetec har vundet Veikkauses udbud

Veikkaus' kontraktsejr på 0,9 MEUR styrker datterselskabet Ubetecin position på det åbne finske spillegældsmarked.

Optomed
Regulatory press release04.09.2026, 14.00

Optomed Oyj: Composition of Optomed's Shareholders' Nomination Board

Optomed
Press release18.08.2026, 13.10

Redeye: Optomed (Q2 Review): Sales miss offset by strong gross margin and cost control

Optomed